Abstract
Oseltamivir phosphate (Tamiflu®) 1 is the only orally active anti-influenza drug. Although constant supply of 1 has been required to avert a possible lethal influenza outbreak, the current commercial synthetic route depends on (-) -shikimic acid 2 of limited availability. New and advantageous synthetic routes to 1 via the catalytic asymmetric reaction have been developed recently, revealing the evolution of synthetic methodology.
